Ustekinumab under the trade name Stelara (also known as CNTO 1275) is an immunosuppressant used to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Ustekinumab as the first biologic therapy for Crohn’s disease is the only treatment for Crohn’s disease that starts with a weight-based, one-time intravenous (IV) infusion induction dose.
DMF, the methyl ester of fumaric acid, combined with three other fumaric acid esters (FAE) was licensed in Germany as an oral therapy for psoriasis under the trade name Fumaderm and Since 2013 it is used to treat adults with relapsing multiple sclerosis under the trade name Tecfidera.
Lenalidomide with the trade name Revlimid is imitative of thalidomide which was introduced in 2004 and developed by modification of the structural backbone of thalidomide. It was intended as a treatment for multiple myeloma at first while thalidomide is an accepted therapeutic treatment for it.